Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor

Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of survival benefit. We investigated whether inhibition of the highly homologous insulin receptor (IR) in addition to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Emma E., Elder, Douglas J. E., Curwen, Jon, Kilgour, Elaine, Hers, Ingeborg, Tavaré, Jeremy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691253/
https://www.ncbi.nlm.nih.gov/pubmed/23826179
http://dx.doi.org/10.1371/journal.pone.0066963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691253/
https://www.ncbi.nlm.nih.gov/pubmed/23826179
http://dx.doi.org/10.1371/journal.pone.0066963

Ejemplares similares